Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Can Johnson & Johnson beat first quarter expectations again?

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Healthcare giant Johnson & Johnson (JNJ:NYSE) is expected to report first-quarter earnings on 16 April before the market open. Consensus forecasts call for EPS (earnings per share) of $2.63, a slight fall of 2% compared with the same period in 2023.
Over the prior four quarters the company has bested consensus estimates by an average of around 5% according to Nasdaq.com.
Fourth-quarter 2023 earnings topped expectations helped by strong sales of J&J’s blockbuster psoriasis treatment Stelara, but the drug faces fresh competition this year from biosimilar versions as J&J loses exclusivity.
The company said it expected volumes of surgical procedures to remain above pre-Covid levels during 2024. In February, medical devices maker Becton Dickinson (BDX:NASDAQ) raised its full year earnings guidance after seeing strong demand for surgical equipment.
On 5 April, J&J boosted its medical devices portfolio after agreeing to purchase Shockwave Medical (SWAV:NASDAQ) for about $12.5 billion or $335 per share, representing a 5% premium to the prior closing price.
News of J&J’s interest surfaced on 26 March, sending shares in Shockwave up 11% on the day.
California-based Shockwave makes devices which use shockwaves to break down calcified plaque in heart vessels.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.
Our website uses cookies to give you a better browsing experience.
You can choose to accept all cookies, or control which we use by clicking 'Manage cookies'. To learn more, read our cookie policy.